Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of the oxaliplatin-paclitaxel combination i.e. evaluation of tumor
response rate using World Health Organization/Union Internationale Contre le Cancer
(WHO/UICC) and Indianapolis tumor marker (human chorionic gonadotropin [hCG], alpha
fetoprotein [AFP]) criteria in metastatic germ cell cancer patients